Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer
Journal of Mammary Gland Biology and Neoplasia · 2012-12 · 17 (3-4) · 251-261
DOI: 10.1007/s10911-012-9268-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Mammary Gland Biology and Neoplasia, online erschienen am 10.10.2012. Verfasst von Yuzhe Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Molecular Targeted Therapy. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, PHS HHS.
Abstract (Originalsprache)
The insulin and insulin like growth factor (IGF) signaling systems are implicated in breast cancer biology. Thus, disrupting IGF/insulin signaling has been shown to have promise in a number of preclinical models. However, human clinical trials have been less promising. Despite evidence of some activity in early phase trials, randomized phase III studies have thus far been unable to show a benefit of blocking IGF signaling in combination with conventional strategies. In breast cancer, combination anti IGF/insulin signaling agents with hormone therapy has not yet proven to have benefit. This inability to translate the preclinical findings into useful clinical strategies calls attention to the need for a deeper understanding of this complex pathway. Development of predictive biomarkers and optimal inhibitory strategies of the IGF/insulin system should yield better clinical strategies. Furthermore, unraveling the interaction between the IGF/insulin pathway and other critical signaling pathways in breast cancer biology, namely estrogen receptor-α (ERα) and epidermal growth factor receptor (EGFR) pathways, provides additional new concepts in designing combination therapies. In this review, we will briefly summarize the current strategies targeting the IGF/insulin system, discuss the possible reasons of success or failure of the existing therapies, and provide potential future directions for research and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Förderung
- NCI NIH HHS
- PHS HHS
Zitieren
APA
Yang, Y., & Yee, D. (2012). Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 17(3-4), 251-261. https://doi.org/10.1007/s10911-012-9268-y
Vancouver
Yang Y, Yee D. Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia. 2012;17(3-4):251-261. doi:10.1007/s10911-012-9268-y
BibTeX
@article{Yang2012,
author = {Yang, Yuzhe and Yee, Douglas},
title = {Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer},
journal = {Journal of Mammary Gland Biology and Neoplasia},
year = {2012},
volume = {17},
number = {3-4},
pages = {251--261},
doi = {10.1007/s10911-012-9268-y}
}
EUVIMED